Introduction: Enteric fever is a severe systemic disease caused by a gram-negative bacillus, Salmonella Enterica serotype Typhi. It commonly occurs in children and young adults. The aim of the research is to address the treatment of enteric fever in pediatric patients including multidrug resistance to first-line drugs. The treatment of enteric fever has been complicated by the worldwide spread of typhoid organisms resistant to ampicillin, trimethoprim-sulfamethoxazole and chloramphenicol. Ceftriaxone damages the germ structure that can kill Salmonella typhi, germ resistance is limited and there are no harmful side effects when administered to children. Discussion: The interest in this pathogen is based on Salmonella typhi strains that have become multiresistant to antibiotics such as some cephalosporins, fluoroquinolones, etc. The importance in terms of antimicrobial resistance lies in the failure of conventional treatments, which causes a delay in effective therapeutic management. Conclusion: Cephalosporins are currently the first line against enteric fever, specifically ceftriaxone and cefixime. In order for the treatment to conclude satisfactorily, it is necessary to observe the disappearance of fever and the decrease of accompanying symptoms.